Jodi Craigo

Dr. Jodi Craigo


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2013 in Viruses
Verified
Journal Article
Open access
PDF file
JCJodi Craigo
Jodi Craigo
RMRonald C. Montelaro
Ronald C. Montelaro
Equine infectious anemia (EIA), identified in 1843 [1] as an infectious disease of horses and as a viral infection in 1904, remains a concern in veterinary medicine today. Equine infectious anemia virus (EIAV) has served as an animal model of HIV-1/AIDS research since the original identification of HIV. Similar to other lentiviruses, EIAV has a high propensity for genomic sequence and antigenic variation, principally in its envelope (Env) proteins. However, EIAV possesses a unique and dynamic disease presentation that has facilitated comprehensive analyses of the interactions between the evolving virus population, progressive host immune responses, and the definition of viral and host correlates of immune control and vaccine efficacy. Summarized here are key findings in EIAV that have provided important lessons toward understanding long term immune control of lentivirus infections and the parameters for development of an enduring broadly protective AIDS vaccine.

1 January 2010 in Current HIV Research
Verified
Journal Article
Closed access
PDF file
JCJodi Craigo
Jodi Craigo
RMRonald C. Montelaro
Ronald C. Montelaro
Equine infectious anemia virus (EIAV) and its associated disease have presented a considerable challenge to veterinary medicine worldwide ever since its identification in the 19th century. Furthermore EIAV, along with its fellow animal lentiviruses, has been utilized as an animal model of HIV-1/AIDS research since the latters identification in the late 20th century. Like all lentiviruses, EIAV has been shown to have a high propensity for genomic sequence and antigenic variation, principally in its envelope (Env) proteins. However, unlike other lentiviruses, EIAV possesses a unique and dynamic disease presentation that enables consummate analyses of the interactions between a virus, host immune system, and the effects of viral evolution on vaccine efficacy. Hence, EIAV provides a novel animal lentivirus system with which to dissect the viral and immune correlates of vaccine efficacy and a system with which to examine vaccine candidates for the ability to elicit broadly protective vaccine immunity. The current review summarizes the key findings that have thus far provided a fundamental understanding of the role of the viral Env in immune control of infection, disease, and vaccine efficacy.

20 October 2009 in Retrovirology
Verified
Journal Article
Open access
PDF file
JCJodi Craigo
Jodi Craigo
SBShannon Barnes
Shannon Barnes
BZBaoshan Zhang
Baoshan Zhang
SCSheila J Cook
Sheila J Cook
LHLaryssa Howe
Laryssa Howe
RMRonald C Montelaro
Ronald C Montelaro
Background: Equine infectious anemia virus (EIAV), a lentivirus that infects horses, has been utilized as an animal model for the study of HIV. Furthermore, the disease associated with the equine lentivirus poses a significant challenge to veterinary medicine around the world. As with all lentiviruses, EIAV has been shown to have a high propensity for genomic sequence and antigenic variation, especially in its envelope (Env) proteins. Recent studies have demonstrated Env variation to be a major determinant of vaccine efficacy, emphasizing the importance of defining natural variation among field isolates of EIAV. To date, however, published EIAV sequences have been reported only for cell-adapted strains of virus, predominantly derived from a single primary virus isolate, EIAVWyoming(EIAVWY).Results: We present here the first characterization of the Env protein of a natural primary isolate from Pennsylvania (EIAVPA) since the widely utilized and referenced EIAVWYstrain. The data demonstrated that the level of EIAVPAEnv amino acid sequence variation, approximately 40% as compared to EIAVWY, is much greater than current perceptions or published reports of natural EIAV variation between field isolates. This variation did not appear to give rise to changes in the predicted secondary structure of the proteins. While the EIAVPAEnv was serologically cross reactive with the Env proteins of the cell-adapted reference strain, EIAVPV(derivative of EIAVWY), the two variant Envs were shown to lack any cross neutralization by immune serum from horses infected with the respective virus strains.Conclusion: Taking into account the significance of serum neutralization to universal vaccine efficacy, these findings are crucial considerations towards successful EIAV vaccine development and the potential inclusion of field isolate Envs in vaccine candidates.

2 April 2013 in Virology Journal
Verified
Journal Article
Open access
PDF file
HEHermancia S Eugene
Hermancia S Eugene
BPBrooke R Pierce-Paul
Brooke R Pierce-Paul
JCJodi Craigo
Jodi Craigo
TRTed M Ross
Ted M Ross
The development of a preventative HIV/AIDS vaccine is challenging due to the diversity of viral genome sequences, especially in the viral envelope (Env160). Since it is not possible to directly match the vaccine strain to the vast number of circulating HIV-1 strains, it is necessary to develop an HIV-1 vaccine that can protect against a heterologous viral challenge. Previous studies from our group demonstrated that a mixture of wild type clade B Envgp160swere able to protect against a heterologous clade B challenge more effectively than a consensus clade B Envgp160vaccine. In order to broaden the immune response to other clades of HIV, in this study rhesus macaques were vaccinated with a polyvalent mixture of purified HIV-1 trimerized consensus Envgp140proteins representing clades A, B, C, and E. The elicited immune responses were compared to a single consensus Envgp140representing all isolates in group M (Con M). Both vaccines elicited anti- Envgp140IgG antibodies that bound an equal number of HIV-1 Envgp160proteins representing clades A, B and C. In addition, both vaccines elicited antibodies that neutralized the HIV-1SF162isolate. However, the vaccinated monkeys were not protected against SHIVSF162p4challenge. These results indicate that consensus Envgp160vaccines, administered as purified Envgp140trimers, elicit antibodies that bind to Envgp160sfrom strains representing multiple clades of HIV-1, but these vaccines did not protect against heterologous SHIV challenge.

13 June 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJodi Craigo
Jodi Craigo
CECorin Ezzelarab
Corin Ezzelarab
SCSheila J. Cook
Sheila J. Cook
LCLiu Chong
Liu Chong
DHDavid Horohov
David Horohov
RMRonald C. Montelaro
Ronald C. Montelaro
Lentiviral envelope (Env) antigenic variation and associated immune evasion present major obstacles to vaccine development. The concept that Env is a critical determinant for vaccine efficacy is well accepted, however defined correlates of protection associated with Env variation have yet to be determined. We reported an attenuated equine infectious anemia virus (EIAV) vaccine study that directly examined the effect of lentiviral Env sequence variation on vaccine efficacy. The study identified a significant, inverse, linear correlation between vaccine efficacy and increasing divergence of the challenge virus Env gp90 protein compared to the vaccine virus gp90. The report demonstrated approximately 100% protection of immunized ponies from disease after challenge by virus with a homologous gp90 (EV0), and roughly 40% protection against challenge by virus (EV13) with a gp90 13% divergent from the vaccine strain. In the current study we examine whether the protection observed when challenging with the EV0 strain could be conferred to animals via chimeric challenge viruses between the EV0 and EV13 strains, allowing for mapping of protection to specific Env sequences. Viruses containing the EV13 proviral backbone and selected domains of the EV0 gp90 were constructed and in vitro and in vivo infectivity examined. Vaccine efficacy studies indicated that homology between the vaccine strain gp90 and the N-terminus of the challenge strain gp90 was capable of inducing immunity that resulted in significantly lower levels of post-challenge virus and significantly delayed the onset of disease. However, a homologous N-terminal region alone inserted in the EV13 backbone could not impart the 100% protection observed with the EV0 strain. Data presented here denote the complicated and potentially contradictory relationship between in vitro virulence and in vivo pathogenicity. The study highlights the importance of structural conformation for immunogens and emphasizes the need for antibody binding, not neutralizing, assays that correlate with vaccine protection.

8 January 2015 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JCJodi Craigo
Jodi Craigo
CECorin Ezzelarab
Corin Ezzelarab
SCSheila J Cook
Sheila J Cook
CLChong Liu
Chong Liu
DHDavid Horohov
David Horohov
RMRonald C Montelaro
Ronald C Montelaro
Lentiviral Envelope (Env) antigenic variation and related immune evasion present major hurdles to effective vaccine development. Centralized Env immunogens that minimize the genetic distance between vaccine proteins and circulating viral isolates are an area of increasing study in HIV vaccinology. To date, the efficacy of centralized immunogens has not been evaluated in the context of an animal model that could provide both immunogenicity and protective efficacy data. We previously reported on a live-attenuated (attenuated) equine infectious anemia (EIAV) virus vaccine, which provides 100% protection from disease after virulent, homologous, virus challenge. Further, protective efficacy demonstrated a significant, inverse, linear relationship between EIAV Env divergence and protection from disease when vaccinates were challenged with viral strains of increasing Env divergence from the vaccine strain Env. Here, we sought to comprehensively examine the protective efficacy of centralized immunogens in our attenuated vaccine platform. We developed, constructed, and extensively tested a consensus Env, which in a virulent proviral backbone generated a fully replication-competent pathogenic virus, and compared this consensus Env to an ancestral Env in our attenuated proviral backbone. A polyvalent attenuated vaccine was established for comparison to the centralized vaccines. Additionally, an engineered quasispecies challenge model was created for rigorous assessment of protective efficacy. Twenty-four EIAV-naïve animals were vaccinated and challenged along with six-control animals six months post-second inoculation. Pre-challenge data indicated the consensus Env was more broadly immunogenic than the Env of the other attenuated vaccines. However, challenge data demonstrated a significant increase in protective efficacy of the polyvalent vaccine. These findings reveal, for the first time, a consensus Env immunogen that generated a fully-functional, replication-competent lentivirus, which when experimentally evaluated, demonstrated broader immunogenicity that does not equate to higher protective efficacy. Our best effort for containment of the global HIV epidemic is the development of a broadly protective vaccine. Current research has focused on vaccines that can generate a protective immune response against numerous strains of the virus. For this reason, vaccines with centralized HIV genes as immunogens, which merge HIV genetic information and potentially protect against multiple viral strains in a single inoculation, are an increasing area of interest to the field. Existing published studies have not evaluated centralized immunogens in the context of attenuated vaccines, which to date, have demonstrated the highest level of vaccine protection in lentiviral studies. Furthermore, centralized immunogen studies have also not included protective efficacy findings accomplished through challenge with highly pathogenic virus strains. In this study we not only examine the immunogenicity of these immunogens in an animal model, but we also for the first time evaluate the ability of centralized immunogens to induce protection against virulent virus challenge.